Navigation Links
OMEGA 180 Binocular Indirect Ophthalmoscope

ProductsOMEGA 180 Binocular Indirect Ophthalmoscope
Company Heine USA Ltd.
Item OMEGA 180 Binocular Indirect Ophthalmoscope
Features 
  • Synchronized adjustment of illumination and observation beams: Instant adjustment allows for stereoscopic examination through pupils down to 1.2mm in diameter
  • Multi-coated precision optics: Exceptional quality of image and illumination without UV and IR
  • Diffuser aperture: Reduces glare and reflexes, simplifying exams
  • Reinforced headband with "lock-up" feature: Comfortable and convenient operation
  • Fine control of light mirror: +/- 4 degree adjustment for difficult examinations
  • Yellow Filter: Increases comfort for light-sensitive patients
  • Aluminum Chassis: Ensures optical alignment and durability
Description The OMEGA 180 features a wide range of innovative features, including HEINE's patented One-Step Small and Variable Pupil Control (U.S. Patent #4,684,227). Stereopsis is maximized in all pupil sizes down to 1.2mm. Heine's unique Diffuser aperture absorbs only 30% of the illumination, making learning BIO easier, and simplifying difficult examinations. A newly incorporated yellow filter for light sensitive patients, along with cobalt blue and red-free filters for all exam situations. The Omega 180 features the highest quality in BIO construction: an aluminum frame for mounting the highest quality German optics, aluminum cylinders and precision "indexed" stops for all aperture and filter controls. These extraordinary Omega 180 features are built into Heine's 100% dustproof housing.

A Binocular Indirect Ophthalmoscope functions by projecting three elements - a light source, right eye observation path, and left eye observation path - simultaneously through the pupil. This illuminates the fundus and allows you to see the retina with both observation paths at the same time. This permits stereopsis or 3-dimensional vision. The variable, but exact, positioning of these three elements is critical to the performance of the BIO. It is Heine's precise, patented, synchronization of illumination and observation paths in the Omega 180 that provides true small pupil performance with stereopsis. Because patients have varying pupil sizes, the single easy-to-use Variable Pupil Control positions the observation paths and light source perfectly for each pupil size. The result: you get optimum viewing clarity and performance every time you use a Heine Omega BIO.

Info Heine USA Ltd.
Customer Service: (800) 367-4872

Related medicine products :

1. HEINE OMEGA 500 Binocular Indirect Ophthalmoscope
2. Binocular Loupes
3. Binocular Loupe C 2.3 x 340 K with Case
4. Binocular Loupe C 2.3 x 450 K with Case
5. Binocular Loupe C 2.3 x 340mm (13in) with Case
6. Binocular Loupe C 2.3 x 450mm (18in) with case
7. Binocular Operation Microscope
8. Digital Binocular Radiusgauge
9. Welch Allyn Binocular Indirect Ophthalmoscope with Diffuser Filter
10. Binocular Indirect Ophthalmoscope with Diffuser and Yellow Filter
11. Binocular Indirect Ophthalmoscope with Yellow Filter
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products:
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease ... neurons may be mistaken for foreign invaders and killed ... way autoimmune diseases like type I diabetes, celiac disease, ... was published April 16, 2014, in Nature Communications ... idea in Parkinson,s disease; but if true, it could ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
(Date:4/17/2014)... YORK (17 April 2014) Population Council scientists and their ... safe, stable, and can prevent the transmission of multiple ... rectum in animals: HIV, herpes simplex virus 2 (HSV-2), ... the first data that the gel is effective against ... efficacy in the vagina against all three viruses of ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... ... MILLS, Md., March 12 Medifast, Inc.,(NYSE: MED ) announced ... 31, 2007., Financial highlights included:, -- Annual revenues ... to the previous year,s fourth quarter; ...
... nodes could alter treatment approach, study suggests , , WEDNESDAY, ... tumors and tissue from patients with early-stage lung cancer ... say researchers at the Johns Hopkins Kimmel Cancer Center. ... approach for lung cancers, which recur within five years ...
... Call Scheduled for Thursday, March 13, 2008, LANCASTER, ... ) today reported financial results for the second quarter,ended ... weeks ended February 3, 2008 were,approximately $34.7 million. Net ... per share., Myron Levy, the Company,s Chairman and ...
... 12 Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), ... proprietary product candidates principally,for use in the hospital ... year ended December 31, 2007, and provided corporate ... and for 2008 to date., "During 2007, ...
... 12, 2008 (BRONX, NY) The unwanted activation ... in two kidney problems that are major causes of ... of Medicine of Yeshiva University have found. Their research, ... failure, is described in the March issue of Nature ...
... been awarded a five-year, $2.1 million grant from the ... of the National Institutes of Health (NIH), to continue ... on research careers. , The grant renews support that ... the training of 26 UI clinician-scientists in pediatrics. They ...
Cached Medicine News:Health News:Medifast Announces Year-end 2007 Financial Results 2Health News:Medifast Announces Year-end 2007 Financial Results 3Health News:Medifast Announces Year-end 2007 Financial Results 4Health News:Medifast Announces Year-end 2007 Financial Results 5Health News:Medifast Announces Year-end 2007 Financial Results 6Health News:Medifast Announces Year-end 2007 Financial Results 7Health News:Medifast Announces Year-end 2007 Financial Results 8Health News:Medifast Announces Year-end 2007 Financial Results 9Health News:Genetic Markers May Predict Lung Cancer Recurrence 2Health News:Herley Reports Second Quarter Results 2Health News:Herley Reports Second Quarter Results 3Health News:Herley Reports Second Quarter Results 4Health News:Herley Reports Second Quarter Results 5Health News:Herley Reports Second Quarter Results 6Health News:Herley Reports Second Quarter Results 7Health News:Herley Reports Second Quarter Results 8Health News:Herley Reports Second Quarter Results 9Health News:Herley Reports Second Quarter Results 10Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 2Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 3Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 4Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 5Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 6Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 7Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 8Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 9Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 10Health News:Novel discovery by Einstein scientists could lead to much-needed kidney failure treatment 2Health News:$2.1 million NIH grant advances U-Iowa child health research 2Health News:$2.1 million NIH grant advances U-Iowa child health research 3
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5